Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. Issue 5 (September 2006)

• Record Type: Journal Article
• Authors: Derosa, Giuseppe; Salvadeo, Sibilla AT; Cicero, Arrigo FG
• Is Part Of: Therapy. Volume 3:Issue 5(2006)
• Page Start: 559
• Page End: 569
• Publication Date: 2006-09
• Subjects: glimepiride -- glycemic control -- PPAR-γγ -- rosiglitazone -- sulphonyurea -- thiazolidinediones; Therapeutics -- Periodicals; Chemotherapy -- Periodicals; 615.505
• DOI: 10.2217/14750708.3.5.559
• Languages: English
• ISSNs: 1475-0708

Abstract

Rosiglitazone and glimepiride are effective antihyperglycemic agents approved for the treatment of Type 2 diabetes mellitus. Primarily, rosiglitazone increases insulin sensitivity, while glimepiride stimulates insulin release from ββ-cells in the pancreas. Combination therapy is often required to achieve effective glycemic control. A fixed-dose formulation of rosiglitazone plus glimepiride has recently been approved in the EU and US for treatment of Type 2 diabetes. Much data demonstrate the advantages of the combination therapy compared with rosiglitazone or glimepiride as monotherapy. Rosiglitazone plus glimepiride is generally well tolerated in all studies and presents a tolerability profile similar to that of monotherapy with rosiglitazone and sulphonylurea. The aim of this review is to present this new fixed-dose combination, which represents a promising new strategy to obtain recommended glycemic control.